Spectral AI showcases DeepView burn diagnostic at SRBC
Spectral AI (Nasdaq: MDAI) used its presence at the Southern Regional Burn Conference (SRBC), held 10–12 September 2026 in Williamsburg, Virginia, to demonstrate the DeepView System for Burn Indication to burn care clinicians and host two key opinion leader presentations supporting the use of AI-assisted multispectral imaging in wound assessment.
The company reported positive engagement at the event, following the FDA's De Novo classification of the DeepView System in May 2026, a milestone that cleared the device for commercial use in the United States. The device had previously received UKCA authorisation in the United Kingdom in February 2024.
How DeepView works
The DeepView System is a non-invasive predictive diagnostic tool that pairs multispectral imaging with a proprietary AI algorithm. It generates an assessment of whether areas within a burn wound are unlikely to heal within 21 days, a clinically significant threshold that guides decisions about surgical intervention. Image acquisition takes 0.2 seconds, with full AI processing completed in approximately 20 to 25 seconds. The underlying model has been trained on a database the company describes as containing more than 340 billion pixels of clinically validated burn wound imagery.
Two KOL presentations at SRBC examined the system's clinical performance. James Hwang, Director of the UAB Burn Center and Chief of Burn Service, presented data showing that AI-assisted evaluation improved physician accuracy in identifying non-healing wounds. Jeffrey Carter, of Burn and Trauma at UMCNO in New Orleans, addressed the repeatability and reproducibility of AI analysis applied to multispectral burn imaging.
Hwang said the diagnostic improvement seen with AI assistance was "encouraging" and suggested the DeepView system "could provide valuable additional insight when making these important treatment determinations."
Vincent Capone, chief executive of Spectral AI, said the company remains focused on driving clinical adoption following regulatory clearance, and that the SRBC provided a useful platform for engaging with burn surgeons and thought leaders.
Market context and competitive landscape
Burn wound depth assessment has historically relied on visual inspection and clinical experience, both of which are subject to inter-observer variability. The push towards objective, device-assisted assessment reflects a broader trend in diagnostics towards AI-augmented clinical decision support tools, a segment that has attracted significant investment and regulatory attention from the FDA over the past three years.
Spectral AI is one of a small number of companies pursuing multispectral or hyperspectral imaging specifically for wound care, a relatively niche segment within the broader medical imaging and diagnostics market. Its BARDA contract, held through subsidiary Spectral MD, provides a government funding backstop that distinguishes its position from purely commercial-stage medical device peers.
The company plans to continue its conference circuit through Q4 2026, with appearances at the Midwest Region Burn Conference in Columbus, Ohio (22–23 October) and the Northeast Region Burn Conference in Boston (13–14 November), where a further KOL presentation on AI-assisted accuracy is scheduled. These events represent the near-term catalysts for broadening clinical awareness ahead of what the company frames as a broader adoption push.